SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

GRI Bio Inc. is trending following positive Phase 2a clinical data for its IPF treatment and a recent 1-for-28 reverse stock split, which has created an exceptionally low float of approximately 500k shares. The community is sharply divided; many anticipate a significant short squeeze comparing it to prior low-float runners, while others express deep skepticism citing the company's history of frequent dilutions and management's perceived lack of trustworthiness. This ongoing debate fuels significant volatility as investors weigh scientific progress against past financial actions.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is experiencing significant upward momentum after securing a pivotal U.S. Air Force contract for advanced swarming capabilities and raising its 2026 revenue guidance. The community is actively discussing the burgeoning defense AI narrative and intense short squeeze potential, driving speculative interest in this autonomous systems innovator.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is facing intense downward pressure, driven by recent analyst downgrades and widespread community belief that the stock is being manipulated for accumulation. While many investors express extreme frustration with its "PainPal" performance despite consistent earnings, substantial share buybacks, and strategic moves into AI commerce and global payments, others view the current valuation as a "criminally undervalued" long-term opportunity, setting high stakes for its next financial disclosure.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending after announcing a $75 million direct offering to a new institutional investor, effectively de-risking its Phase 3 MASH trial funding and igniting community debate. Many view this as a strategic move that strengthens negotiating leverage for a potential buyout, especially given Barclays' recent 'Overweight' rating and coverage initiation. However, some investors are concerned about dilution and the offering price, even as discussions highlight pemvidutide's 'best-in-class' profile in the competitive MASH market.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a strong rally in partner company Redwire, intensifying speculation around imminent government AI contracts for defense and border security. Investors are actively debating a pending vote to increase authorized shares, with many anticipating a significant short squeeze and drawing comparisons to Palantir's growth trajectory.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending following its latest earnings report, which highlighted record order intake and robust 2026 guidance, largely fueled by accelerating AI-related demand. The community is actively debating the company's indispensable monopoly in EUV lithography and the increased capital expenditures from major chipmakers, even amidst some discussions around high valuation and geopolitical risks. As a core semiconductor bellwether, ASML's performance remains a crucial indicator for the industry's durability in the ongoing AI and chip supercycle.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is a top discussion point following an FDA clinical hold on its RGX-111 and RGX-121 gene therapy programs due to a safety event, triggering sharp market volatility. Despite initial panic, many investors are calling the reaction an overcorrection, emphasizing that the primary value-driving programs for wet AMD and Duchenne muscular dystrophy remain unaffected. The community is actively debating the broader impact of this regulatory action on the company's prospects, especially concerning the upcoming PDUFA decision for RGX-121.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending following a mixed quarterly report where increased customer traffic signals progress in its turnaround strategy, though profitability challenges persist. The community is actively debating whether growing transaction volumes can translate into sustained earnings growth amid ongoing margin pressures and competitive market dynamics. Investors are closely watching if management's initiatives, including simplified menus and store experience improvements, will drive future profitability.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to circulating reports of a potential merger with Automation Anywhere, which has ignited varied community reactions. This news, coupled with significant new contracts from the U.S. Army and Department of Health and Human Services, is fueling intense speculation about a potential short squeeze given the stock's high short interest and its enterprise AI market position.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending following a strong fourth-quarter earnings report that surpassed expectations and provided a bullish multi-year outlook. The community is actively discussing the company's commitment to return capital to shareholders through significant buybacks and dividends, alongside continued growth in its crucial fiber and 5G businesses. Investors view AT&T as a compelling value and a defensive play, despite competitive pressures, fueled by optimism around its strategic investments in advanced connectivity and satellite partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


lotus303

lotus303